Bleomycin is an antineoplastic agent that is known for its potential for fatal lung toxicity. Cell injury occurs through the formation of free radicals. Timely detection of bleomycin-induced pneumonitis (BIP) can be difficult and it is vital to keep a low index of suspicion in patients receiving bleomycin. We describe a patient with Hodgkin’s lymphoma who died of bleomycin-induced lung injury in our intensive care unit. We discuss treatment options and review the literature.
Back to issue - Download PDF